Italia markets closed

ADMA Biologics, Inc. (ADMA)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
6,05+0,01 (+0,17%)
In data: 02:20PM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente6,04
Aperto6,03
Denaro6,05 x 100
Lettera6,13 x 100
Min-Max giorno6,01 - 6,12
Intervallo di 52 settimane3,06 - 6,76
Volume855.795
Media Volume2.550.600
Capitalizzazione1,402B
Beta (5 anni mensile)0,43
Rapporto PE (ttm)N/D
EPS (ttm)-0,13
Prossima data utili08 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A8,38
  • GlobeNewswire

    ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update

    2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss(2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million Adjusted EBITDA Growth Expected Over the Remainder of 2023 FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively Conference Call Scheduled for Today at 4:30 p.m. ET R

  • GlobeNewswire

    ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023

    Conference Call Scheduled for August 9, 2023, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report second quarter financial results on August 9, 2023, after the U.S. financial markets close. ADMA’s management team will host a liv

  • GlobeNewswire

    ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA

    FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J. and BOCA RATON, Fla. and DALLAS, Ga., July 19, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced th